Pharmacokinetics of gemcitabine and 2',2'- Difluorodeoxyuridine in a patient with ascites

Pharmacotherapy

Volumn 20, Issue 10, 2000, Pages 1204-1207

  Delauter, Brian J ^a,b   Ramanathan, Ramesh K ^a,c   Egorin, Merrill J ^a,c,d   Stover, Lori L ^a,c   Zuhowski, Eleanor G ^a,b   Plunkett, William ^e   Zamboni, William C ^a,c  

^a Program of Molecular Therapeutics and Drug Discovery   (United States)

^b School of Pharmacy   (United States)

^c School of Medicine   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLOXURIDINE; GEMCITABINE;

ADULT; ARTICLE; ASCITES; BLOOD SAMPLING; CASE REPORT; DRUG DISPOSITION; DRUG EFFECT; ENZYME METABOLISM; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY FUNCTION; LIVER FUNCTION; PROTEIN PHOSPHORYLATION;

ABDOMINAL PAIN; ADENOCARCINOMA; ANTIMETABOLITES, ANTINEOPLASTIC; ASCITES; CASE REPORT; CATHETERS, INDWELLING; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DEOXYCYTIDINE; FEMALE; FLOXURIDINE; FLUOROURACIL; HUMAN; MIDDLE AGE; PANCREATIC NEOPLASMS; SUPPORT, U.S. GOV'T, P.H.S.; URINARY TRACT INFECTIONS;

EID: 0033781777     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.20.15.1204.34586     Document Type: Article

References (14)

1. Gemcitabine: Metabolism, mechanisms of action, and self-potentiation
2. Modulatory activity of 2',2'-difluorodeoxycytidine on the phosphorylation and cytotoxicity of arabinosyl nucleosides
3. Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-β-D-arabinofuranosylcytosine
4. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine
5. Phase I study and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and leukemia group B 9565
6. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial
7. Gemcitabine: A promising new agent in the treatment of advanced urothelial cancer
8. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer
9. Effect of pleural effusions on high-dose methotrexate kinetics
10. Treatment of locally unresectable carcinoma of the pancreas; comparison of combined modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone
11. Randomized phase II trial of dose intense gemcitabine by standard infusion vs. fixed dose rate in metastatic pancreatic adenocarcinoma
12. Saturation of 2',2'-difluorodeoxycytidine 5'-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine
13. Absorption and distribution kinetics
14. Gemcitabine in leukemia: A phase I clinical, plasma, and cellular pharmacology study